ECC4703 + Semaglutide for Obesity

Not yet recruiting at 14 trial locations

Overseen By Eccogene Clinical Trials

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Eccogene

Must not be taking: GLP-1 agonists, THR-β agonists

Disqualifiers: Diabetes, Liver disease, Alcohol use, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 20 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

Are You a Good Fit for This Trial?

Inclusion Criteria

4. HbA1c ≤6.5%.

5. Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 (per CKD-EPI 2021 formula).

1. Capable of providing written informed consent and complying with all trial procedures.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive ECC4703 or placebo orally daily and semaglutide subcutaneously once weekly

20 weeks

Weekly visits for semaglutide administration

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• ECC4703
• Semaglutide

How Is the Trial Designed?

Group I: Arm 1: ECC4703 + semaglutide Experimental Treatment 2 Interventions

ECC4703 orally QD + semaglutide SC once weekly

Group II: Arm 2: Placebo + semaglutide Placebo Group 2 Interventions

Placebo orally QD + semaglutide SC once weekly

Who Is Running the Clinical Trial?

Eccogene

Lead Sponsor

Trials

5

Recruited

300+